Population Pharmacokinetics: Some Observations in Pediatric Modeling for Drug Clearance.

about

Population Pharmacokinetics: Some Observations in Pediatric Modeling for Drug Clearance.

Item

http://www.wikidata.org/entity/Q38838930

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Population Pharmacokinetics: Some Observations in Pediatric Modeling for Drug Clearance.

@en

type

Item

label

Population Pharmacokinetics: Some Observations in Pediatric Modeling for Drug Clearance.

@en

prefLabel

Population Pharmacokinetics: Some Observations in Pediatric Modeling for Drug Clearance.

@en

P1476

Population Pharmacokinetics: Some Observations in Pediatric Modeling for Drug Clearance

@en

P2093

Million A Tegenge

http://www.w3.org/2001/XMLSchema#string

P2860

Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations?

Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis

A bodyweight-dependent allometric exponent for scaling clearance across the human life-span.

The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults.

Theoretical versus empirical allometry: Facts behind theories and application to pharmacokinetics.

Prediction of drug clearance in children: an evaluation of the predictive performance of several models.

Prediction of Drug Clearance in Premature and Mature Neonates, Infants, and Children ≤2 Years of Age: A Comparison of the Predictive Performance of 4 Allometric Models.

Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models.

Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?

From trial and error to trial simulation. Part 2: an appraisal of current beliefs in the design and analysis of clinical trials for antidepressant drugs.

P2888

s40262-017-0542-4

P304

1567-1576

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40262-017-0542-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Iftekhar Mahmood

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084742094

http://www.w3.org/2001/XMLSchema#string

P698

28405936

http://www.w3.org/2001/XMLSchema#string